This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
A forum of leading clinical development
and medical experts stewarding advances
in science and clinical research for the
continuum of metabolic diseases
Events
8th Metabolic Continuum Roundtable™ Annual Meeting – MASH Disease Monitoring and Treatment Decisions Using Non-Invasive Tests: Readiness of the NITs Toolbox
May, 2025 | Amsterdam, Netherlands
Contact Us »
7th Metabolic Continuum Roundtable™ Annual Meeting – Steatotic Liver Disease (MASLD/MASH): Disease Burden – Patient Reported Outcomes – Health Economics: Payor & Societal Perspectives
November 10, 2023 | Boston, MA
More Information »
6th NASH Roundtable™ Forum – Clinical Trials with Non-Invasive Tests (NITs) Instead of Histology: Fact or Fancy?
November 5, 2022 | Washington, DC
More information »
5th NASH Roundtable™ Virtual Forum – Is Digital Pathology a Game-Changer for Histology for NASH Drug Development?
June 16, 2022 | Virtual
More information »
Resources
Fact Sheet: Metabolic Continuum Roundtable™, leading clinical development experts addressing challenges in NASH drug development
Member Co-authored Publications
July 12, 2024
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials. Read More »
June 17, 2024
Is digital pathology the new standard in MASH trials? Read More »
June 12, 2024
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD). Read More »
June 11, 2024
The fibroblast hormone endotrophin is a biomarker of mortality in chronic diseases. Read More »
June 10, 2024
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Read More »
June 8, 2024
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. Read More »